Fennec announces City of Hope IST testing PEDMARK in adult testicular germ cell tumors

FENNEC PHARMACEUTICALS INC.

Phase I study (NCT07218913) evaluating PEDMARK to prevent cisplatin-induced ototoxicity in adults with stage II-III metastatic testicular germ cell tumors.
Principal investigator: Alexander Chehrazi-Raffle, M.D., at City of Hope, Duarte, CA.
PEDMARK is currently approved for pediatric patients with localized solid tumors; this expands investigation into adult metastatic setting.
Multiple other investigator-initiated studies submitted or in advanced contracting stages.
Fennec's CMO cites need for hearing protection in cisplatin-treated survivors; study aims to change standard of care.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.